← Back to Clinical Trials
Recruiting NCT04699734

NCT04699734 Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04699734
Status Recruiting
Phase
Sponsor University of Aarhus
Condition Painful Diabetic Neuropathy
Study Type INTERVENTIONAL
Enrollment 16 participants
Start Date 2020-09-08
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Xylocaine 1%NaCl 9mg/ml

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16 participants in total. It began in 2020-09-08 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the present study is to evaluate the role of peripheral afferent input for spontaneous pain in painful diabetic polyneuropathy

Eligibility Criteria

Inclusion Criteria: * Aged 18 years or older. * Probably diabetic neuropathy confirmed using the Toronto criteria in a "conservative manner", i.e. three out of three symptoms/signs of neuropathy must be present (sensory neuropathy symptoms, distal reduced sensibility, reduced ankle reflexes) 7. * Definite or probable neuropathic pain for minimum the last 6 months * Mean pain intensity at \> 4 NRS the last week17. Since we expect a large effect of the block it is not necessary to discontinue pain medication. Exclusion Criteria: * Other causes of pain in the same area or other pain that cannot be distinguished from the neuropathic pain. * Unable to understand and speak Danish. * Non-cooperative. * Warfarin or other medication that contraindicate regional anesthesia. * Infection in the injection area. * Allergy to lidocaine. * Pregnancy or lactating (fertile women must to show negative pregnancy test or use anticonception). * Severe psychiatric disease e.g. severe depression during the last 6 months. * Alcohol or drug abuse.

Contact & Investigator

Central Contact

Ellen L Schaldemose, MD

✉ ells@clin.au.dk

📞 +45 93501942

Principal Investigator

Ellen L Schaldemose, MD

PRINCIPAL INVESTIGATOR

Danish Pain Research Center, Aarhus University

Frequently Asked Questions

Who can join the NCT04699734 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Painful Diabetic Neuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04699734 currently recruiting?

Yes, NCT04699734 is actively recruiting participants. Contact the research team at ells@clin.au.dk for enrollment information.

Where is the NCT04699734 trial being conducted?

This trial is being conducted at Aarhus N, Denmark.

Who is sponsoring the NCT04699734 clinical trial?

NCT04699734 is sponsored by University of Aarhus. The principal investigator is Ellen L Schaldemose, MD at Danish Pain Research Center, Aarhus University. The trial plans to enroll 16 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology